Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

News SummaryMost relevantAll newsSector news 

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
04/25/2012 | 02:01pm CET

Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
12/09 ELI LILLY AND : Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITI..
12/09 ASTRAZENECA PLC (NYSE : AZN) Cuts Jobs, Signs New Collaboration With Eli Lilly a..
12/09 ELI LILLY AND : Assigned Ornamental Design Patent
12/09 ELI LILLY AND : Lilly and AstraZeneca to Develop Second Potentially Disease-Modi..
12/09 ELI LILLY AND : Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITI..
12/09 ELI LILLY AND : Lilly Announces Detailed Results of Solanezumab Phase 3 EXPEDITI..
12/08 ELI LILLY AND : Findings from Eli Lilly Update Knowledge of Atomoxetine Therapy ..
12/08 ELI LILLY AND CO (NYSE : LLY) Discusses Job Cuts
12/07 ELI LILLY AND : U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce t..
12/07 PFIZER : Judicial Panel on Multidistrict Litigation Issues Order on Viagra Produ..
More news
Sector news : Pharmaceuticals - NEC
12/09 FTSE records best week since July, Sky surges 27 percent on Fox bid
12/09DJASTRAZENECA : FDA Accepts License Application for Durvalumab
12/09DJBayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/09 Lilly not giving up on Alzheimer's, teams up with AstraZeneca to develop earl..
12/09 Lilly presents detailed results from failed late-stage study of solanezumab i..
12/06 Early Data For Next Generation Of Imbruvica's Challengers
12/05 INCYTE : Another Celgene?
Financials ($)
Sales 2016 20 997 M
EBIT 2016 4 643 M
Net income 2016 3 086 M
Debt 2016 2 304 M
Yield 2016 3,03%
P/E ratio 2016 25,61
P/E ratio 2017 20,14
EV / Sales 2016 3,68x
EV / Sales 2017 3,53x
Capitalization 74 903 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 84,1 $
Spread / Average Target 24%
Consensus details
EPS Revisions
More Estimates Revisions
John C. Lechleiter Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Thomas F. Bumol Senior VP-Biotechnology & Autoimmunity Research
Timothy J. Garnett Chief Medical Officer
Jan M. Lundberg Executive Vice President-Science & Technology
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO-20.26%74 903
JOHNSON & JOHNSON9.29%305 407
ROCHE HOLDING LTD.-17.58%193 824
PFIZER INC.-4.15%192 367
NOVARTIS AG-18.49%182 959
MERCK & CO., INC.15.92%168 820
More Results